Table 1. Baseline characteristics of study patients.
| Patients (N = 156) | |
| General demographics | |
| Age (year) | 60.34 ± 10.15 |
| Male gender (%) | 127 (81.4) |
| Clinical condition | |
| STEMI (%) | 2 (1.3) |
| NSTEMI (%) | 16 (10.3) |
| Unstable angina (%) | 58 (37.2) |
| Stable angina (%) | 80 (51.3) |
| Risk factors | |
| Hypertension (%) | 116 (74.4) |
| Diabetes (%) | 57 (36.5) |
| Current smoker (%) | 56 (35.9) |
| Prior myocardial infarction (%) | 16 (10.3) |
| Prior stroke (%) | 9 (5.8) |
| PAOD (%) | 1 (0.6) |
| Hyperlipidemia (%) | 106 (67.9) |
| Heart failure (%) | 5 (3.2) |
| Prior CABG (%) | 1 (0.6) |
| ESRD on maintenance hemodialysis (%) | 2 (1.3) |
| Laboratory examination | |
| Creatinine (mg/dL) (exclude ESRD) | 1.12 ± 1.13 |
| HbA1C (%) | 6.56 ± 1.21 |
| Total cholesterol (mg/dL) | 161.29 ± 38.32 |
| LDL-cholesterol (mg/dL) | 92.75 ± 32.57 |
| HDL-cholesterol (mg/dL) | 44.22 ± 11.47 |
| Syntax score | 12.42 ± 8.77 |
| F/U time (days) | 383.60 ± 292.35 |
| DAPT | |
| Aspirin + clopidogrel or ticagrelor | 136 (87.2) |
| Clopidogel + cilostazol | 8 (5.1) |
| Only aspirin or clopidogrel or ticagrelor | 12 (7.7) |
Data are expressed as mean ± SD or as number (percentage).
CABG, coronary artery bypass grafting; DAPT, dual anti-platelet therapy; ESRD, end stage renal disease; F/U, follow-up; HbA1C, glycohemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein; NSTEMI, non ST segment elevation myocardial infarction; PAOD, peripheral arterial occlusive disease; STEMI, ST segment elevation myocardial infarction.